279 related articles for article (PubMed ID: 36189315)
1. New insights into CAR T cell-mediated killing of tumor cells.
Espie D; Donnadieu E
Front Immunol; 2022; 13():1016208. PubMed ID: 36189315
[TBL] [Abstract][Full Text] [Related]
2. Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism.
Marofi F; Tahmasebi S; Rahman HS; Kaigorodov D; Markov A; Yumashev AV; Shomali N; Chartrand MS; Pathak Y; Mohammed RN; Jarahian M; Motavalli R; Motavalli Khiavi F
Stem Cell Res Ther; 2021 Mar; 12(1):217. PubMed ID: 33781320
[TBL] [Abstract][Full Text] [Related]
3. CAR T-cell behavior and function revealed by real-time imaging.
Espie D; Donnadieu E
Semin Immunopathol; 2023 Mar; 45(2):229-239. PubMed ID: 36688965
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
[TBL] [Abstract][Full Text] [Related]
5. Bispecific CAR T Cells against EpCAM and Inducible ICAM-1 Overcome Antigen Heterogeneity and Generate Superior Antitumor Responses.
Yang Y; McCloskey JE; Yang H; Puc J; Alcaina Y; Vedvyas Y; Gomez Gallegos AA; Ortiz-Sánchez E; de Stanchina E; Min IM; von Hofe E; Jin MM
Cancer Immunol Res; 2021 Oct; 9(10):1158-1174. PubMed ID: 34341066
[TBL] [Abstract][Full Text] [Related]
6. Intercellular Adhesion Molecule-1 as Target for CAR-T-Cell Therapy of Triple-Negative Breast Cancer.
Wei H; Wang Z; Kuang Y; Wu Z; Zhao S; Zhang Z; Li H; Zheng M; Zhang N; Long C; Guo W; Nie C; Yang H; Tong A
Front Immunol; 2020; 11():573823. PubMed ID: 33072116
[TBL] [Abstract][Full Text] [Related]
7. Immune Checkpoint Proteins, Metabolism and Adhesion Molecules: Overlooked Determinants of CAR T-Cell Migration?
Simula L; Ollivier E; Icard P; Donnadieu E
Cells; 2022 Jun; 11(11):. PubMed ID: 35681548
[TBL] [Abstract][Full Text] [Related]
8. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
9. Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma.
Huang H; Wu HW; Hu YX
J Zhejiang Univ Sci B; 2020 Jan.; 21(1):29-41. PubMed ID: 31898440
[TBL] [Abstract][Full Text] [Related]
10. [New Research Advances on Chimeric Antigen Receptor T Cells in the Treatment of Relapsed and Refractory Multiple Myeloma-Review].
Zhang FR; Li X; Liu J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Aug; 27(4):1316-1320. PubMed ID: 31418399
[TBL] [Abstract][Full Text] [Related]
11. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.
Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A
Front Immunol; 2021; 12():665970. PubMed ID: 34475869
[TBL] [Abstract][Full Text] [Related]
12. Disrupting N-glycan expression on tumor cells boosts chimeric antigen receptor T cell efficacy against solid malignancies.
Greco B; Malacarne V; De Girardi F; Scotti GM; Manfredi F; Angelino E; Sirini C; Camisa B; Falcone L; Moresco MA; Paolella K; Di Bono M; Norata R; Sanvito F; Arcangeli S; Doglioni C; Ciceri F; Bonini C; Graziani A; Bondanza A; Casucci M
Sci Transl Med; 2022 Jan; 14(628):eabg3072. PubMed ID: 35044789
[TBL] [Abstract][Full Text] [Related]
13. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA
Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319
[TBL] [Abstract][Full Text] [Related]
14. Decoding the mechanisms of chimeric antigen receptor (CAR) T cell-mediated killing of tumors: insights from granzyme and Fas inhibition.
Montalvo MJ; Bandey IN; Rezvan A; Wu KL; Saeedi A; Kulkarni R; Li Y; An X; Sefat KMSR; Varadarajan N
Cell Death Dis; 2024 Feb; 15(2):109. PubMed ID: 38307835
[TBL] [Abstract][Full Text] [Related]
15. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
Kosti P; Maher J; Arnold JN
Front Immunol; 2018; 9():1104. PubMed ID: 29872437
[TBL] [Abstract][Full Text] [Related]
16. Obstacles and Coping Strategies of CAR-T Cell Immunotherapy in Solid Tumors.
Miao L; Zhang Z; Ren Z; Tang F; Li Y
Front Immunol; 2021; 12():687822. PubMed ID: 34093592
[TBL] [Abstract][Full Text] [Related]
17. Infectious complications of chimeric antigen receptor (CAR) T-cell therapies.
Gea-Banacloche JC
Semin Hematol; 2023 Jan; 60(1):52-58. PubMed ID: 37080711
[TBL] [Abstract][Full Text] [Related]
18. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
Gauthier J; Yakoub-Agha I
Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
[TBL] [Abstract][Full Text] [Related]
19. In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update.
Soundara Rajan T; Gugliandolo A; Bramanti P; Mazzon E
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899932
[TBL] [Abstract][Full Text] [Related]
20. CAR-T cells, from principle to clinical applications.
Bourbon E; Ghesquières H; Bachy E
Bull Cancer; 2021 Oct; 108(10S):S4-S17. PubMed ID: 34920806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
